Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-RT: Durvalumab after radiation monotherapy in stage III chemoradiotherapy-ineligible NSCLC
jRCT1090220434Phase 2Completed
- Sponsor
- Kyoto Prefectural University of Medicine
- Start
- Aug 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Kyoto Prefectural University of Medicine. Primary endpoint: PFS rate. Started Aug 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1090220434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220434.